Chidamide in Combination With Vincristine Metronomic Chemotherapy for Advanced Triple-negative Breast Cancer
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
The mechanism of action of cidabenamide and the advantages of vincristine metronomic
chemotherapy make it possible to combine the two drugs. Therefore, it is necessary to conduct
a prospective study to investigate the value of chidamide in combination with vincristine
metronomic treatment for triple-negative breast cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences